Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

References

• de Lavallade H, El-Cheikh J, Faucher C, . Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008;41:953–960.
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Morris C, . High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574–2579.
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, . Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99 - 03 trial) with tandem autologous stem cell transplantation (IFM99 - 04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–3480.
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, . A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–1120.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Perez-Simon JA, Sureda A, . A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591–3593.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Martinez-Lopez J, Serna JD, . Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438–446.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Shimoni A, Nagler A, . Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18: 659–662.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Wu K, Verdonck LF, . The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103: 4362–4364.
   PubMed Web of Science ®Google Scholar
• Salama M, Nevill T, Marcellus D, . Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179–1184.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kroger N, Hegenbart U, . Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135–1141.
   PubMed Web of Science ®Google Scholar
• Kroger N, Badbaran A, Lioznov M, . Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009;37:791–798.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Shimoni A, Nagler A, . Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18: 659–662.
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia 2004;18:1541–1542; author reply 1542–1543.
   PubMed Web of Science ®Google Scholar
• Champlin R, Giralt S, Przepiorka D, . Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res 1992;377:385–394; discussion 395–398.
   PubMedGoogle Scholar
• Munshi NC, Anderson KC, Bergsagel PL, . Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696–4700.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, . Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Mohty M, Attal M, Marit G, . Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005;35:165–169.
   PubMed Web of Science ®Google Scholar
• Dazzi F, Szydlo RM, Craddock C, . Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67–71.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, . Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103: 1548–1556.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Mackinnon S, Williams CD, . Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9:257–265.
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH, . Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261–1268.
   PubMed Web of Science ®Google Scholar
• Kernan NA, Collins NH, Juliano L, . Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986;68:770–773.
   PubMed Web of Science ®Google Scholar
• Miller JS, Weisdorf DJ, Burns LJ, . Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007;110: 2761–2763.
   PubMed Web of Science ®Google Scholar
• Giralt S, Hester J, Huh Y, . CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86: 4337–4343.
   PubMed Web of Science ®Google Scholar
• Byrne JL, Fairbairn J, Davy B, . Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant 2003;31:157–161.
   PubMed Web of Science ®Google Scholar
• Chong G, Byrnes G, Szer J, . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000;26:1011–1015.
   PubMed Web of Science ®Google Scholar
• Kumar S, Fonseca R, Dispenzieri A, . Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101: 1715–1717.
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, . Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196–1198.
   PubMed Web of Science ®Google Scholar